GenFleet Therapeutics Inc. (“GenFleet” or the “Company”) recently announced the completion of its Series B financing of nearly RMB 400 million. The investment was jointly led by CDH Investments and Shenzhen Capital Group. Other participants included South China Venture Capital, Panlin Capital, and BoCom International, among others. Existing investors Sinopharm Capital, Lake Bleu Capital, and Highlight Capital also increased their holdings in the round.

Proceeds from the current round of financing will primarily be used to advance GenFleet’s existing clinical pipeline (including clinical trial development and international expansion), expand its immunology platform, launch new projects, and develop R&D and manufacturing facilities.

GenFleet is a company dedicated to the development of global first-in-class drugs. The Company’s products are focused on tumor and immunological biomechanics and clinical transformations, focusing on multiple therapeutic areas including tumors and autoimmune diseases. Its drugs are all self-developed and original products, and are currently in the process of clinical verification.

The Company’s first independent R&D project was approved by the CFDA in less than two years, and the pipeline of follow-up products is also advancing steadily. The Company expects additional projects to be approved for clinical trials both in China and internationally later this year.

About CEC Capital Group

Founded in 2000, CEC Capital Group is one of China’s leading investment banks focusing on the three major industries of healthcare, consumer, and TMT. The company is headquartered in Beijing, with offices in Shanghai. Its US affiliate, China eCapital Partners, LLC, has offices in Los Angeles and San Francisco.

In the three years from 2017 to 2019, CEC Capital Group has participated in financing and M&A transactions valued at a total of more than RMB 100 billion. In addition to its investment banking business, CEC Capital Group has been managing an RMB fund and a USD fund since 2014.

CEC Capital Group has the healthcare industry’s largest dedicated investment banking coverage team in China, with comprehensive coverage of the entire ecosystem and a market-leading position in the industry. The firm has advised on the largest number of healthcare-related private capital financing transactions over the past three years among China-based investment banks.